We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+17.69%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$9.21M
Cap. Flow
+$6.26M
Cap. Flow %
4.65%
Top 10 Hldgs %
39.93%
Holding
69
New
12
Increased
31
Reduced
2
Closed
2
Avg Time Held Equity + Options
3.8 quarters
Top 10 Avg Time Held Equity + Options
2 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
4 quarters
Top 10 Avg Time Held Equity only
2.6 quarters
Top 20 Avg Time Held Equity only
3.5 quarters

Top Buys

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$3.25M
2
AXSM icon
Axsome Therapeutics
AXSM
+$1.28M
3
HRTX icon
Heron Therapeutics
HRTX
+$439K
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$435K
5
SCYX icon
SCYNEXIS
SCYX
+$419K

Top Sells

Rank Stock Value
1
QGENF
QIAGEN NV
QGENF
+$3.13M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$809K
3
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$249K

Sector Composition

Rank Sector Weight
1 Healthcare 77.47%
2 Miscellaneous 21.89%
3 Real Estate 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$10B
$9.01M 6.69%
130,000
– –
2016 Q2
3 quarters
IBB icon
2
iShares Biotechnology ETF
IBB
$10.5B
$7.33M 5.44%
75,000
– –
2016 Q2
3 quarters
MRK icon
3
Merck
MRK
$359B
$5.32M 3.95%
87,718
– –
2015 Q3
6 quarters
ALKS icon
4
Alkermes
ALKS
$6.75B
$4.92M 3.66%
84,190
+1,894
+2% +$107K
2014 Q4
9 quarters
BMY icon
5
Bristol-Myers Squibb
BMY
$118B
$4.89M 3.63%
90,000
– –
2015 Q3
6 quarters
INCY icon
6
Incyte
INCY
$22.6B
$4.71M 3.5%
35,240
+209
+0.6% +$26.6K
2014 Q4
9 quarters
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$30.4B
$4.62M 3.43%
90,121
+1,337
+2% +$61.8K
2014 Q4
9 quarters
NKTR icon
8
Nektar Therapeutics
NKTR
$1.36B
$4.37M 3.25%
12,419
+130
+1% +$29.2K
2014 Q4
9 quarters
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$4.37M 3.24%
69,512
+1,202
+2% +$75K
2014 Q4
9 quarters
ALXN
10
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.24M 3.15%
+35,000
New +$4.51M
2017 Q1
0 quarters
BIB icon
11
ProShares Ultra NASDAQ Biotechnology
BIB
$91.4M
$4.1M 3.04%
85,000
– –
2016 Q3
2 quarters
PFE icon
12
Pfizer
PFE
$162B
$3.84M 2.85%
118,364
– –
2016 Q1
4 quarters
AZN icon
13
AstraZeneca
AZN
$246B
$3.74M 2.77%
60,000
– –
2015 Q2
7 quarters
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$129B
$3.72M 2.76%
34,006
+649
+2% +$57.1K
2014 Q4
9 quarters
CELG
15
DELISTED
Celgene Corp
CELG
$3.51M 2.6%
28,197
+911
+3% +$109K
2014 Q4
9 quarters
MTD icon
16
Mettler-Toledo International
MTD
$31.3B
$3.44M 2.55%
7,188
– –
2014 Q4
9 quarters
AGIO icon
17
Agios Pharmaceuticals
AGIO
$1.84B
$3.35M 2.49%
57,410
+1,886
+3% +$90.4K
2015 Q3
6 quarters
ILMN icon
18
Illumina
ILMN
$41.8B
$3.32M 2.46%
19,976
+478
+2% +$75.3K
2014 Q4
9 quarters
QGEN icon
19
Qiagen
QGEN
$9.36B
$3.24M 2.4%
+105,399
New +$3.25M
2017 Q1
0 quarters
AMGN icon
20
Amgen
AMGN
$226B
$3.18M 2.36%
19,401
+658
+4% +$109K
2014 Q4
9 quarters
IONS icon
21
Ionis Pharmaceuticals
IONS
$7.26B
$3.17M 2.35%
78,900
+1,350
+2% +$60.6K
2014 Q4
9 quarters
BIIB icon
22
Biogen
BIIB
$33.9B
$3.12M 2.31%
11,404
+532
+5% +$150K
2014 Q4
9 quarters
REGN icon
23
Regeneron Pharmaceuticals
REGN
$78.5B
$3.11M 2.31%
8,035
+351
+5% +$130K
2014 Q4
9 quarters
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$10.7B
$2.89M 2.14%
32,911
+1,332
+4% +$119K
2014 Q4
9 quarters
GSK icon
25
GSK
GSK
$94B
$2.53M 1.88%
48,000
– –
2016 Q2
3 quarters
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2017 Portfolio in Review

As of Q1 2017, Opus Point Partners Management held 69 positions worth $135M, up 7.3% from $126M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Opus Point Partners Management deployed $6.26M of net new capital in Q1 2017, opening 12 new positions and adding to 31 existing holdings. Its largest new stake was Qiagen: 105,399 shares worth $3.24M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $809K trimmed.

  • Opus Point Partners Management's largest Q1 2017 buy was Qiagen: 105,399 shares worth $3.24M.
  • Opus Point Partners Management added most to Precigen in Q1 2017, an estimated $189K increase.
  • Opus Point Partners Management's biggest Q1 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $809K.
  • Opus Point Partners Management fully exited QIAGEN NV in Q1 2017, selling an estimated $3.13M.
  • Opus Point Partners Management's ten largest holdings make up 40% of its $135M portfolio in Q1 2017.
  • Opus Point Partners Management opened 12 new positions and closed 2 in Q1 2017.
  • Opus Point Partners Management's portfolio value rose 7.3% quarter-over-quarter to $135M.

Based on Opus Point Partners Management's 13F filing for Q1 2017, filed 15 May 2017.